<DOC>
	<DOCNO>NCT00279760</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , parallel multiple dose study provide safety , preliminary efficacy , immunogenicity information use BMS-188667 BMS-224818 subject RA</brief_summary>
	<brief_title>Phase I/II Multiple-Dose LEA29Y v CTLAG4Ig v Placebo Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis RA &lt; 5 year Functional class I , II , II define American College Rheumatology ( ACR ) criterion . Must fail least 1 Disease Modifying AnitRheumatic Drug ( DMARD ) Joint count 10 swollen 12 tender . Erythrocyte Sedimentation Rate ( ESR ) &gt; 28mm/rr norning stiffness &gt; 45 minute . Women men willing use accept form contraception . Active vasculitis Treatment another investigational drug within 30 day History asthma , angioedema , anaphylaxix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>